CXCR4 and carcinoma: However, the altered biodistribution of γδ[T2] cells may have compromised their use in solid tumor immunotherapy, despite the frequent production of CXCR4 ligands47 and expression of E-selectin on the vasculature of both human and mouse carcinomas.48